Symbols

VIR

Vir Biotechnology·NASDAQ

--(--)

VIR Profile

Vir Biotechnology, Inc.

A biotech company developing innovative treatments for infectious diseases, including hepatitis B and COVID-19

Industry

Biological Technology

Established Date

04/07/2016

Listing Date

10/11/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

367

Fiscal Year Ends

12-31

Website

www.vir.bio

Security Type

Common stock

Office address

1800 Owens Street, Suite 900, San Francisco, California 94158

Business

Introduction

Vir Biotechnology, Inc., was incorporated under the laws of the State of Delaware on April 7, 2016. As a clinical-stage biopharmaceutical company, VIR is committed to boosting the immune system to develop innovative therapies for serious infectious diseases and cancer. The company's approach focuses on addressing the complex mechanisms by which these threats evade immune defense. Vir's clinical development pipeline includes therapies for delta hepatitis virus and various solid tumors, and ongoing clinical programs and trials show promise for new standards of care. The company utilizes its proprietary technology platforms DAISY and PRO-XTEN to optimize antibody development. With a leadership team experienced in immunology, infectious diseases and oncology, VIR is committed to changing lives through its transformative therapies.